Implantable Cisplatin Synthesis Microdevice for Regional Chemotherapy

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Delivery Systems

Background:

• Cisplatin is a vital chemotherapy drug approved by the FDA in 1978 for various cancers.
• Systemic cisplatin delivery causes painful side effects, limiting its clinical application.
• Regional chemotherapy with advanced drug delivery systems can mitigate toxicity and improve tumor drug accumulation.

Purpose of the Study:

• To develop and evaluate an implantable microdevice capable of synthesizing cisplatin in situ for regional chemotherapy.
• To assess the efficacy of microdevice-synthesized cisplatin in preclinical cancer models.

Main Methods:

• A rice-grain sized, ultrasonically powered microdevice was designed to synthesize cisplatin.
• The microdevice produced 0.7 mg of cisplatin within 1 hour under ultrasonic irradiation (400 mW cm⁻²).
• The cytotoxic effects of the synthesized cisplatin were evaluated using in vitro murine breast cancer cells and ex vivo liver tissue.

Main Results:

• The microdevice successfully synthesized cisplatin in situ.
• Microdevice-mediated cisplatin delivery demonstrated significantly higher cytotoxic activity against murine breast cancer cells in vitro.
• Ex vivo experiments on liver tissue also indicated enhanced efficacy of the synthesized cisplatin.

Conclusions:

• The developed cisplatin synthesis microdevice is a viable tool for regional chemotherapy.
• This technology offers a potential alternative to conventional cisplatin delivery, minimizing systemic side effects.
• The microdevice-mediated approach shows promise for improved cancer treatment outcomes.